Viatris Inc.

EFFEXOR® met primary and secondary efficacy endpoints in a Phase 3 study for GAD in Japanese adults, showing superior anxiolytic effects and a well-tolerated safety profile. The study achieved its primary objective of superiority over placebo at 8 weeks based on the Hamilton Anxiety Rating Scale (HAM-A) total score change. All seven secondary efficacy endpoints were also met, confirming superiority compared to placebo. EFFEXOR® was generally well-tolerated, with low discontinuation rates due to adverse events and no serious TEAEs observed. The PMDA submission is targeted for 2025.

The Global Drug Device Combination Products Market is projected to reach USD 174.4 billion in 2024 and USD 389.7 billion by 2033 at a CAGR of 9.3%. The US market is expected to grow from USD 59.1 billion in 2024 to USD 125.6 billion by 2033 at a CAGR of 8.7%. Key drivers include technological advancements and rising chronic diseases. Major players include Medtronic, Abbott Laboratories, and Boston Scientific.

DelveInsight's 2024 Alzheimer's Disease Pipeline Insight report details 110+ companies developing 120+ therapies, including Neurodon, Sangamo Therapeutics, and others. Key therapies like NRDN-201, ST-501, and Blarcamesine are in various clinical phases. Regulatory milestones include FDA's conventional approval of Leqembi in 2023. The report covers drug mechanisms, clinical studies, and market dynamics.

Viatris Inc., formed by Mylan and Upjohn, navigates pharma challenges with 5% stock rise vs. S&P 500's 2%. Market cap $14.44B, EPS forecasts $2.66/$2.70. NA GX segment growth driven by Breyna, NPL guidance raised to $500-600M. OTC divestiture by mid-2024 aims for leverage target of 3x. Analysts cautious, Barclays 'Underweight'. Medium-term pipeline promising, FDA GA Depot meeting crucial.